Upon maximum tolerated dose determination , patients with low-RAS signature , high-IGF@ expression ovarian cancer were randomised to dalotuzumab/MK -@ versus dalotuzumab/ridaforolimus , whereas patients with high IGF@/low IGF@ expression colorectal cancer received dalotuzumab/MK -@ .